The Biotech Growth Trust PLC (LON:BIOG - Get Free Report) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 843.02 ($10.90) and traded as low as GBX 762.43 ($9.86). The Biotech Growth Trust shares last traded at GBX 763 ($9.86), with a volume of 89,042 shares traded.
The Biotech Growth Trust Price Performance
The stock has a market cap of £223.41 million, a P/E ratio of 2.63 and a beta of 0.50. The business has a 50-day simple moving average of GBX 840.73 and a 200 day simple moving average of GBX 931.11. The company has a current ratio of 0.59, a quick ratio of 0.00 and a debt-to-equity ratio of 11.02.
Insider Activity at The Biotech Growth Trust
In related news, insider Nicola Shepherd acquired 1,000 shares of the stock in a transaction dated Monday, January 13th. The stock was bought at an average price of GBX 846 ($10.94) per share, for a total transaction of £8,460 ($10,935.88). Also, insider Hamish Baillie bought 1,200 shares of the company's stock in a transaction that occurred on Thursday, December 19th. The shares were bought at an average price of GBX 856 ($11.07) per share, for a total transaction of £10,272 ($13,278.18). 0.71% of the stock is currently owned by company insiders.
The Biotech Growth Trust Company Profile
(
Get Free Report)
The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).
Recommended Stories
Before you consider The Biotech Growth Trust, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and The Biotech Growth Trust wasn't on the list.
While The Biotech Growth Trust currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
